个人中心 - 老虎社区

YBinvest

IP属地：未知

帖子 · 57帖子 · 57
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- YBinvestYBinvest
  ·2021-12-07
  1
  非常抱歉，此主贴已删除
  1,165 评论
  4
  分享
  举报
- YBinvestYBinvest
  ·2021-12-07
  Nice move
  Vaccine stocks rallied in morning trading
  Vaccine stocks rallied in morning trading.Novavax,Corvus Pharmaceuticals,BioNTech SE,Vir Biotechnolo
  Vaccine stocks rallied in morning trading
  1,329 评论
  5
  分享
  举报
- YBinvestYBinvest
  ·2021-12-06
  Like pls
  Vaccine stocks mixed in morning trading
  Vaccine stocks mixed in morning trading.Moderna and BioNTech SE plunged more than 12% while Johnson
  Vaccine stocks mixed in morning trading
  1,146 2
  7
  分享
  举报
- YBinvestYBinvest
  ·2021-11-30
  $BioNTech SE(BNTX)$Investors may be worried that the vaccine is not effective against thenew variant but isn’t that exactly how the vaccine stock create new revenue when the current vaccine is not effective? Certainly an opportunity to load more when people are worried.
  1,638 1
  2
  分享
  举报
- YBinvestYBinvest
  ·2021-11-24
  Like pls
  10 Biggest Price Target Changes For Wednesday
  Needham raised Analog Devices, Inc. price target from $200 to $205. Analog Devices shares fell 0.6%
  10 Biggest Price Target Changes For Wednesday
  1,047 2
  6
  分享
  举报
- YBinvestYBinvest
  ·2021-11-19
  Like pls
  Roblox stock jumped 5% in morning trading
  Roblox stock jumped 5% in morning trading as Morgan Stanley sets Street-high price target on it. Mo
  Roblox stock jumped 5% in morning trading
  868 1
  6
  分享
  举报
- YBinvestYBinvest
  ·2021-11-18
  Like pls
  非常抱歉，此主贴已删除
  946 2
  4
  分享
  举报
- YBinvestYBinvest
  ·2021-11-16
  Like pls
  Nasdaq Index turned down in morning trading with Tesla's market value fell below 1 trillion dollars
  Nasdaq Index turned down in morning trading with Tesla's market value fell below 1 trillion dollars.
  Nasdaq Index turned down in morning trading with Tesla's market value fell below 1 trillion dollars
  1,213 1
  4
  分享
  举报
- YBinvestYBinvest
  ·2021-11-12
  Like pls
  The Smartest Stocks to Buy With $20 Right Now
  A small amount of money can go a long way when invested in these top-notch stocks.
  The Smartest Stocks to Buy With $20 Right Now
  831 2
  3
  分享
  举报
- YBinvestYBinvest
  ·2021-11-10
  Like pls
  3 Ultra-High-Yield Dividend Stocks With 42% to 50% Upside, According to Wall Street
  These income stocks, with yields ranging between 8% and 8.3%, have Wall Street's attention.
  3 Ultra-High-Yield Dividend Stocks With 42% to 50% Upside, According to Wall Street
  1,116 1
  3
  分享
  举报
暂无粉丝

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

老虎社区侵权投诉指引

中国互联网举报中心·北京互联网举报中心

网络谣言曝光台·扫黄打非举报中心

网络110报警服务

© 2018-2024 老虎社区版权所有

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

qrcode

关注我们

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3576666566979913","uuid":"3576666566979913","gmtCreate":1613578339326,"gmtModify":1613578339326,"name":"YBinvest","pinyin":"ybinvest","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":15,"headSize":257,"tweetSize":57,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.01","exceedPercentage":"93.92%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.07.03","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.04%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":5,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":606518814,"gmtCreate":1638891987704,"gmtModify":1638891987915,"author":{"id":"3576666566979913","authorId":"3576666566979913","name":"YBinvest","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576666566979913","authorIdStr":"3576666566979913"},"themes":[],"htmlText":"1","listText":"1","text":"1","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606518814","repostId":"1112161791","repostType":2,"isVote":1,"tweetType":1,"viewCount":1165,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606511204,"gmtCreate":1638891964836,"gmtModify":1638891965083,"author":{"id":"3576666566979913","authorId":"3576666566979913","name":"YBinvest","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576666566979913","authorIdStr":"3576666566979913"},"themes":[],"htmlText":"Nice move","listText":"Nice move","text":"Nice move","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606511204","repostId":"1112161791","repostType":2,"repost":{"id":"1112161791","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638888869,"share":"https://www.laohu8.com/m/news/1112161791?lang=&edition=full","pubTime":"2021-12-07 22:54","market":"us","language":"en","title":"Vaccine stocks rallied in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1112161791","media":"Tiger Newspress","summary":"Vaccine stocks rallied in morning trading.Novavax,Corvus Pharmaceuticals,BioNTech SE,Vir Biotechnolo","content":"<p>Vaccine stocks rallied in morning trading.Novavax,Corvus Pharmaceuticals,BioNTech&nbsp;SE,Vir Biotechnology,Innovio Pharmaceuticals,Acorda Therapeutics&nbsp;and&nbsp;Moderna&nbsp;climbed between 3% and 14%.</p>\n<p><img src=\"https://static.tigerbbs.com/514b1f8a10d604332a0a0560b9b41019\" tg-width=\"406\" tg-height=\"596\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccine stocks rallied in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccine stocks rallied in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-07 22:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Vaccine stocks rallied in morning trading.Novavax,Corvus Pharmaceuticals,BioNTech&nbsp;SE,Vir Biotechnology,Innovio Pharmaceuticals,Acorda Therapeutics&nbsp;and&nbsp;Moderna&nbsp;climbed between 3% and 14%.</p>\n<p><img src=\"https://static.tigerbbs.com/514b1f8a10d604332a0a0560b9b41019\" tg-width=\"406\" tg-height=\"596\" referrerpolicy=\"no-referrer\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CRVS":"Corvus Pharmaceuticals, Inc.","VIR":"Vir Biotechnology, Inc.","NVAX":"诺瓦瓦克斯医药","BNTX":"BioNTech SE","PFE":"辉瑞","INO":"伊诺维奥制药","REGN":"再生元制药公司","ACOR":"阿索尔达生物制药公司","MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1112161791","content_text":"Vaccine stocks rallied in morning trading.Novavax,Corvus Pharmaceuticals,BioNTech SE,Vir Biotechnology,Innovio Pharmaceuticals,Acorda Therapeutics and Moderna climbed between 3% and 14%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1329,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606908595,"gmtCreate":1638804582914,"gmtModify":1638804583082,"author":{"id":"3576666566979913","authorId":"3576666566979913","name":"YBinvest","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576666566979913","authorIdStr":"3576666566979913"},"themes":[],"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/606908595","repostId":"1172118771","repostType":2,"repost":{"id":"1172118771","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638803122,"share":"https://www.laohu8.com/m/news/1172118771?lang=&edition=full","pubTime":"2021-12-06 23:05","market":"us","language":"en","title":"Vaccine stocks mixed in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1172118771","media":"Tiger Newspress","summary":"Vaccine stocks mixed in morning trading.Moderna and BioNTech SE plunged more than 12% while Johnson ","content":"<p>Vaccine&nbsp;stocks&nbsp;mixed&nbsp;in&nbsp;morning&nbsp;trading.Moderna and BioNTech SE plunged more than 12% while Johnson &amp; Johnson and&nbsp;AstraZeneca&nbsp;rose&nbsp;about 2%.</p>\n<p><img src=\"https://static.tigerbbs.com/a026a8b3f73899e06c8e4913061f6618\" tg-width=\"410\" tg-height=\"722\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccine stocks mixed in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccine stocks mixed in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-06 23:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Vaccine&nbsp;stocks&nbsp;mixed&nbsp;in&nbsp;morning&nbsp;trading.Moderna and BioNTech SE plunged more than 12% while Johnson &amp; Johnson and&nbsp;AstraZeneca&nbsp;rose&nbsp;about 2%.</p>\n<p><img src=\"https://static.tigerbbs.com/a026a8b3f73899e06c8e4913061f6618\" tg-width=\"410\" tg-height=\"722\" referrerpolicy=\"no-referrer\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学","LLY":"礼来","MRNA":"Moderna, Inc.","MRK":"默沙东","JNJ":"强生","SNY":"赛诺菲安万特","BNTX":"BioNTech SE","PFE":"辉瑞","GSK":"葛兰素史克","REGN":"再生元制药公司"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1172118771","content_text":"Vaccine stocks mixed in morning trading.Moderna and BioNTech SE plunged more than 12% while Johnson & Johnson and AstraZeneca rose about 2%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1146,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609843904,"gmtCreate":1638269821656,"gmtModify":1638269821751,"author":{"id":"3576666566979913","authorId":"3576666566979913","name":"YBinvest","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576666566979913","authorIdStr":"3576666566979913"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>Investors may be worried that the vaccine is not effective against thenew variant but isn’t that exactly how the vaccine stock create new revenue when the current vaccine is not effective? Certainly an opportunity to load more when people are worried.","listText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>Investors may be worried that the vaccine is not effective against thenew variant but isn’t that exactly how the vaccine stock create new revenue when the current vaccine is not effective? Certainly an opportunity to load more when people are worried.","text":"$BioNTech SE(BNTX)$Investors may be worried that the vaccine is not effective against thenew variant but isn’t that exactly how the vaccine stock create new revenue when the current vaccine is not effective? Certainly an opportunity to load more when people are worried.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/609843904","isVote":1,"tweetType":1,"viewCount":1638,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":874884731,"gmtCreate":1637757989008,"gmtModify":1637757989095,"author":{"id":"3576666566979913","authorId":"3576666566979913","name":"YBinvest","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576666566979913","authorIdStr":"3576666566979913"},"themes":[],"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/874884731","repostId":"1132868023","repostType":4,"repost":{"id":"1132868023","kind":"news","pubTimestamp":1637757490,"share":"https://www.laohu8.com/m/news/1132868023?lang=&edition=full","pubTime":"2021-11-24 20:38","market":"us","language":"en","title":"10 Biggest Price Target Changes For Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=1132868023","media":"Benzinga","summary":"Needham raised Analog Devices, Inc. price target from $200 to $205. Analog Devices shares fell 0.6% ","content":"<ul>\n <li>Needham raised&nbsp;<b>Analog Devices, Inc.</b>&nbsp;price target from $200 to $205. Analog Devices shares fell 0.6% to $181.37 in pre-market trading.</li>\n <li>HC Wainwright &amp; Co. raised the price target on&nbsp;<b>Palatin Technologies, Inc.</b>&nbsp;from $2 to $5. Palatin Technologies shares fell 5.6% to $0.3250 in pre-market trading.</li>\n <li>Baird raised&nbsp;<b>Titan Machinery Inc.</b>&nbsp;price target from $37 to $41. Titan Machinery shares fell 2.2% to $37.45 in pre-market trading.</li>\n <li>Telsey Advisory Group lowered&nbsp;<b>The Gap, Inc.</b>&nbsp;price target from $33 to $24. Gap shares dipped 20.5% to $18.68 in pre-market trading.</li>\n <li>Cowen &amp; Co. lowered the price target on&nbsp;<b>Jack in the Box Inc.</b>&nbsp;from $140 to $130. Jack in the Box shares fell 2.9% to close at $93.00 on Tuesday.</li>\n <li>Piper Sandler cut the price target for&nbsp;<b>Anaplan, Inc.</b>&nbsp;from $77 to $48. Anaplan shares dipped 17.8% to $42.77 in pre-market trading.</li>\n <li>RBC Capital boosted&nbsp;<b>Chevron Corporation</b>&nbsp;price target from $130 to $145. Chevron shares rose 0.4% to $116.73 in pre-market trading.</li>\n <li>Jefferies cut the price target on&nbsp;<b>Nordstrom, Inc.</b>&nbsp;from $48 to $30. Nordstrom shares fell 26.9% to $23.34 in pre-market trading.</li>\n <li>Telsey Advisory Group increased the price target for&nbsp;<b>Dollar Tree, Inc.</b>&nbsp;from $132 to $175. Dollar Tree shares rose 0.3% to $145.12 in pre-market trading.</li>\n <li>Keybanc reduced&nbsp;<b>Autodesk, Inc.</b>&nbsp;price target from $365 to $350. Autodesk shares fell 13.9% to $261.90 in pre-market trading.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>10 Biggest Price Target Changes For Wednesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n10 Biggest Price Target Changes For Wednesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-24 20:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/markets/penny-stocks/21/11/24271788/10-biggest-price-target-changes-for-wednesday><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Needham raised Analog Devices, Inc. price target from $200 to $205. Analog Devices shares fell 0.6% to $181.37 in pre-market trading.\nHC Wainwright & Co. raised the price target on Palatin ...</p>\n\n<a href=\"https://www.benzinga.com/markets/penny-stocks/21/11/24271788/10-biggest-price-target-changes-for-wednesday\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DLTR":"美元树公司","ADSK":"欧特克","PTN":"Palatin Technologies Inc","JWN":"诺德斯特龙","ADI":"亚德诺","TITN":"Titan Machinery Inc","CVX":"雪佛龙","JACK":"Jack In The Box Inc"},"source_url":"https://www.benzinga.com/markets/penny-stocks/21/11/24271788/10-biggest-price-target-changes-for-wednesday","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1132868023","content_text":"Needham raised Analog Devices, Inc. price target from $200 to $205. Analog Devices shares fell 0.6% to $181.37 in pre-market trading.\nHC Wainwright & Co. raised the price target on Palatin Technologies, Inc. from $2 to $5. Palatin Technologies shares fell 5.6% to $0.3250 in pre-market trading.\nBaird raised Titan Machinery Inc. price target from $37 to $41. Titan Machinery shares fell 2.2% to $37.45 in pre-market trading.\nTelsey Advisory Group lowered The Gap, Inc. price target from $33 to $24. Gap shares dipped 20.5% to $18.68 in pre-market trading.\nCowen & Co. lowered the price target on Jack in the Box Inc. from $140 to $130. Jack in the Box shares fell 2.9% to close at $93.00 on Tuesday.\nPiper Sandler cut the price target for Anaplan, Inc. from $77 to $48. Anaplan shares dipped 17.8% to $42.77 in pre-market trading.\nRBC Capital boosted Chevron Corporation price target from $130 to $145. Chevron shares rose 0.4% to $116.73 in pre-market trading.\nJefferies cut the price target on Nordstrom, Inc. from $48 to $30. Nordstrom shares fell 26.9% to $23.34 in pre-market trading.\nTelsey Advisory Group increased the price target for Dollar Tree, Inc. from $132 to $175. Dollar Tree shares rose 0.3% to $145.12 in pre-market trading.\nKeybanc reduced Autodesk, Inc. price target from $365 to $350. Autodesk shares fell 13.9% to $261.90 in pre-market trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1047,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":876569499,"gmtCreate":1637332681824,"gmtModify":1637332688124,"author":{"id":"3576666566979913","authorId":"3576666566979913","name":"YBinvest","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576666566979913","authorIdStr":"3576666566979913"},"themes":[],"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/876569499","repostId":"1147403588","repostType":4,"repost":{"id":"1147403588","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637332561,"share":"https://www.laohu8.com/m/news/1147403588?lang=&edition=full","pubTime":"2021-11-19 22:36","market":"us","language":"en","title":"Roblox stock jumped 5% in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1147403588","media":"Tiger Newspress","summary":"Roblox stock jumped 5% in morning trading as Morgan Stanley sets Street-high price target on it.\n\nMo","content":"<p>Roblox stock jumped 5% in morning trading&nbsp;as&nbsp;Morgan Stanley sets Street-high price target on it.</p>\n<p><img src=\"https://static.tigerbbs.com/8f2970feb5e54b6d376b4d16f41917d5\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p>\n<p>Morgan Stanley analyst Brian Nowak said in a note to clients Wednesday evening that the stock still has more room to run.</p>\n<p>“RBLX’s 3Q results and analyst day highlighted its early leadership in the metaverse and continued innovation to capitalize on materially higher long-term monetization opportunity. At 3Q results, we were particularly encouraged by the October trends ... as we think they speak to RBLX’s better than appreciated growth runway/ability to continue growing its user base, engagement and monetization even through reopening,” Nowak wrote.</p>\n<p>Morgan Stanley raised its price target on Roblox to $150 per share from $88. The new target is 20% above where the stock closed Wednesday and is the highest among major Wall Street firms, according to FactSet. Shares rose nearly 4% in premarket trading Thursday.</p>\n<p>The increased focus of companies on the metaverse should help Roblox expand its revenue opportunities in the years ahead, according to Morgan Stanley.</p>\n<p>“We were most encouraged by management’s statement that ‘in the next 3-5 years, all brands will have a Roblox Strategy’, as we believe this speaks to the company’s focus on driving higher branded monetization,” the note said.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roblox stock jumped 5% in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoblox stock jumped 5% in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-19 22:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Roblox stock jumped 5% in morning trading&nbsp;as&nbsp;Morgan Stanley sets Street-high price target on it.</p>\n<p><img src=\"https://static.tigerbbs.com/8f2970feb5e54b6d376b4d16f41917d5\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p>\n<p>Morgan Stanley analyst Brian Nowak said in a note to clients Wednesday evening that the stock still has more room to run.</p>\n<p>“RBLX’s 3Q results and analyst day highlighted its early leadership in the metaverse and continued innovation to capitalize on materially higher long-term monetization opportunity. At 3Q results, we were particularly encouraged by the October trends ... as we think they speak to RBLX’s better than appreciated growth runway/ability to continue growing its user base, engagement and monetization even through reopening,” Nowak wrote.</p>\n<p>Morgan Stanley raised its price target on Roblox to $150 per share from $88. The new target is 20% above where the stock closed Wednesday and is the highest among major Wall Street firms, according to FactSet. Shares rose nearly 4% in premarket trading Thursday.</p>\n<p>The increased focus of companies on the metaverse should help Roblox expand its revenue opportunities in the years ahead, according to Morgan Stanley.</p>\n<p>“We were most encouraged by management’s statement that ‘in the next 3-5 years, all brands will have a Roblox Strategy’, as we believe this speaks to the company’s focus on driving higher branded monetization,” the note said.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RBLX":"Roblox Corporation"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1147403588","content_text":"Roblox stock jumped 5% in morning trading as Morgan Stanley sets Street-high price target on it.\n\nMorgan Stanley analyst Brian Nowak said in a note to clients Wednesday evening that the stock still has more room to run.\n“RBLX’s 3Q results and analyst day highlighted its early leadership in the metaverse and continued innovation to capitalize on materially higher long-term monetization opportunity. At 3Q results, we were particularly encouraged by the October trends ... as we think they speak to RBLX’s better than appreciated growth runway/ability to continue growing its user base, engagement and monetization even through reopening,” Nowak wrote.\nMorgan Stanley raised its price target on Roblox to $150 per share from $88. The new target is 20% above where the stock closed Wednesday and is the highest among major Wall Street firms, according to FactSet. Shares rose nearly 4% in premarket trading Thursday.\nThe increased focus of companies on the metaverse should help Roblox expand its revenue opportunities in the years ahead, according to Morgan Stanley.\n“We were most encouraged by management’s statement that ‘in the next 3-5 years, all brands will have a Roblox Strategy’, as we believe this speaks to the company’s focus on driving higher branded monetization,” the note said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":868,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":876917840,"gmtCreate":1637248865047,"gmtModify":1637248867909,"author":{"id":"3576666566979913","authorId":"3576666566979913","name":"YBinvest","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576666566979913","authorIdStr":"3576666566979913"},"themes":[],"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/876917840","repostId":"1137107762","repostType":4,"isVote":1,"tweetType":1,"viewCount":946,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":871032378,"gmtCreate":1636992775550,"gmtModify":1636992775672,"author":{"id":"3576666566979913","authorId":"3576666566979913","name":"YBinvest","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576666566979913","authorIdStr":"3576666566979913"},"themes":[],"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/871032378","repostId":"1105194762","repostType":4,"repost":{"id":"1105194762","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636990511,"share":"https://www.laohu8.com/m/news/1105194762?lang=&edition=full","pubTime":"2021-11-15 23:35","market":"us","language":"en","title":"Nasdaq Index turned down in morning trading with Tesla's market value fell below 1 trillion dollars","url":"https://stock-news.laohu8.com/highlight/detail?id=1105194762","media":"Tiger Newspress","summary":"Nasdaq Index turned down in morning trading with Tesla's market value fell below 1 trillion dollars.","content":"<p>Nasdaq Index turned&nbsp;down&nbsp;in morning trading with Tesla's market value fell below 1 trillion dollars.<img src=\"https://static.tigerbbs.com/201cf466934fa60cc63374e64a0db551\" tg-width=\"772\" tg-height=\"563\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/c5d7f306762ab2851bfef58a237e2d55\" tg-width=\"772\" tg-height=\"560\" referrerpolicy=\"no-referrer\">According to the documents disclosed by the SEC, Musk sold 1.2 million Tesla Motors shares on the 12th. So far, Musk has sold about 6.34 million Tesla Motors shares since November 8. Musk promised to sell 10% of Tesla Motors shares, that is, 17.05 million shares, so Musk has sold only 37.1% of his promise, and needs to sell at least 10.7 million shares of Tesla Motors shares. In addition, Musk hinted that he would sell more Tesla Motors shares; Michael Burry, a \"big bear\", tweeted that Musk only wanted to cash out at a high position.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nasdaq Index turned down in morning trading with Tesla's market value fell below 1 trillion dollars</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNasdaq Index turned down in morning trading with Tesla's market value fell below 1 trillion dollars\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-15 23:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Nasdaq Index turned&nbsp;down&nbsp;in morning trading with Tesla's market value fell below 1 trillion dollars.<img src=\"https://static.tigerbbs.com/201cf466934fa60cc63374e64a0db551\" tg-width=\"772\" tg-height=\"563\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/c5d7f306762ab2851bfef58a237e2d55\" tg-width=\"772\" tg-height=\"560\" referrerpolicy=\"no-referrer\">According to the documents disclosed by the SEC, Musk sold 1.2 million Tesla Motors shares on the 12th. So far, Musk has sold about 6.34 million Tesla Motors shares since November 8. Musk promised to sell 10% of Tesla Motors shares, that is, 17.05 million shares, so Musk has sold only 37.1% of his promise, and needs to sell at least 10.7 million shares of Tesla Motors shares. In addition, Musk hinted that he would sell more Tesla Motors shares; Michael Burry, a \"big bear\", tweeted that Musk only wanted to cash out at a high position.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite","TSLA":"特斯拉"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1105194762","content_text":"Nasdaq Index turned down in morning trading with Tesla's market value fell below 1 trillion dollars.According to the documents disclosed by the SEC, Musk sold 1.2 million Tesla Motors shares on the 12th. So far, Musk has sold about 6.34 million Tesla Motors shares since November 8. Musk promised to sell 10% of Tesla Motors shares, that is, 17.05 million shares, so Musk has sold only 37.1% of his promise, and needs to sell at least 10.7 million shares of Tesla Motors shares. In addition, Musk hinted that he would sell more Tesla Motors shares; Michael Burry, a \"big bear\", tweeted that Musk only wanted to cash out at a high position.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1213,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":879236041,"gmtCreate":1636727400855,"gmtModify":1636727400992,"author":{"id":"3576666566979913","authorId":"3576666566979913","name":"YBinvest","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576666566979913","authorIdStr":"3576666566979913"},"themes":[],"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/879236041","repostId":"2182094779","repostType":4,"repost":{"id":"2182094779","kind":"highlight","pubTimestamp":1636723680,"share":"https://www.laohu8.com/m/news/2182094779?lang=&edition=full","pubTime":"2021-11-12 21:28","market":"us","language":"en","title":"The Smartest Stocks to Buy With $20 Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2182094779","media":"Motley Fool","summary":"A small amount of money can go a long way when invested in these top-notch stocks.","content":"<p>Time and again, Wall Street has shown investors the power of patience.</p>\n<p>Over the past 71 years, the broad-based <b>S&amp;P 500</b> has undergone 38 double-digit percentage corrections. Despite the regularity of these moves lower, every crash and correction throughout this period was eventually erased by a bull market rally. To put things succinctly, if investors buy great companies and allow their investment theses to play out over long periods of time, their chances of building wealth is very high.</p>\n<p>Best of all, with most online brokerages discarding minimum deposit requirements and commission fees, investors can begin or further their trek to financial independence with any amount of cash -- even $20. If you have $20 ready to put to work in the market, and it won't be needed to cover bills or other essential costs, the following trio of companies are the smartest stocks to buy right now.</p>\n<h2>Exelixis</h2>\n<p>One of the savviest stocks patient investors can buy right now with $20 is cancer-drug developer <b>Exelixis</b> (NASDAQ:EXEL).</p>\n<p>Last week, Exelixis announced its third-quarter operating results, which failed to hit the mark and sent its shares down by more than 10%. Sales of lead-drug Cabometyx were shy of Wall Street's expectations, which caused Exelixis to lower the upper end of its full-year sales outlook. Generally, lowering sales expectations will be met with frowns on Wall Street.</p>\n<p>However, this short-term weakness should be viewed as an opportunity, especially with the company's price-to-earnings-growth ratio (PEG ratio) below 0.4. A PEG ratio below 1 is typically considered \"undervalued.\"</p>\n<p>Although the landscape for first-line advanced renal cell carcinoma (RCC) is competitive, Cabometyx has demonstrated the ability to grow sales by a sustained double-digit percentage in RCC and advanced hepatocellular carcinoma. On an annual run-rate basis, Cabometyx is pacing more than $1 billion in sales -- and it's not done growing.</p>\n<p>More importantly, Exelixis' lead drug is being examined in close to six dozen clinical trials as a monotherapy or combination treatment. If even a handful of these trials yield a positive result, label-expansion opportunities and organic growth could send Cabometyx to north of $2 billion in peak annual sales.</p>\n<p>Additionally, Exelixis' robust cash position ($1.8 billion in cash, cash equivalents, and restricted cash) and healthy operating cash flow have allowed it to reignite its internal research engine. This includes advancing internally developed compounds into phase 1 studies, as well as signing collaboration agreements to potentially expand its cancer-drug pipeline.</p>\n<p>It's not often you can marry growth and value with the same company, but that's exactly what investors can do with biotech stock Exelixis.</p>\n<h2>Jushi Holdings</h2>\n<p>Some of the most deeply discounted growth stocks can be found in the marijuana industry, which is why U.S. multi-state operator (MSO) <b>Jushi Holdings</b> (OTC:JUSHF) makes for a smart buy with $20.</p>\n<p>To start with, don't be concerned about a lack of cannabis reform in Washington. While life would undoubtedly be easier for pot stocks if lawmakers would simply follow the overwhelming will of the public and legalize cannabis, allowing individual states to legalize and regulate their pot industries is working fine. Thus far, 36 states have given the green light to weed in some capacity, which is providing growth opportunities for MSOs like Jushi.</p>\n<p>In relative terms, Jushi is a small fry, with only 26 operating dispensaries at the moment. Comparatively, a handful of MSOs have in the neighborhood of (or more than) 100 open locations. But Jushi isn't about reckless expansion. Its management team favors methodical expansion in core markets. For Jushi, these core states are Pennsylvania, Illinois, and Virginia.</p>\n<p>The reason management has chosen these states is due to their billion-dollar sales potential (Illinois hit $1 billion in legal pot revenue in 2020) and their limited-license status. In limited-license cannabis markets, regulators purposely limit how many dispensary licenses are issued in total, as well as to a single business. For a smaller player like Jushi, this competitive protection ensures it'll have a fair shot to build up its brand(s) and garner a loyal following in these core markets.</p>\n<p>Something else impressive about Jushi, and <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the reasons I plan to be a long-term shareholder, is the participation of management and insiders. Of the first $250 million raised by the company, $45 million came from insiders and execs. When leadership has skin in the game right alongside their investors, good things tend to happen.</p>\n<p>Jushi is expected to turn the corner to recurring profitability in 2022 and the company's growing sales faster than virtually all other MSOs. The company checks all the appropriate boxes for growth investors.</p>\n<h2>Viatris</h2>\n<p>On the other hand, if value runs through your blood, generic-drug giant <b>Viatris</b> (NASDAQ:VTRS) is one of the smartest stocks you can buy right now with $20.</p>\n<p>Roughly a year ago, Viatris was born from the combination of <b>Pfizer</b>'s established drug unit Upjohn with generic-drug developer Mylan. Due to generic-drug price weakness throughout the industry, the company's first year as a public company has been one to forget. However, this near-term underperformance represents the perfect opportunity for patient investors to nab an exceptionally inexpensive and profitable drug stock.</p>\n<p>There were a number of reasons Upjohn and Mylan tied the knot. First off, there were clear-cut cost synergies. The company expects to recognize more than $500 million in cost synergies this year, with well over $1 billion in annual cost reductions by 2023.</p>\n<p>As a combined company, Viatris is also in a better position to tackle its outstanding debt. Through the first six months of 2021, $1.15 billion in debt was repaid. By the end of 2023, $6.5 billion in debt should be repaid, which represents a quarter of the company's combined debt ($26 billion), as of November 2020.</p>\n<p>Beyond just trimming the fat, Viatris should be able to kick-start its internal drug research in 2024 once debt levels are reduced to more favorable levels. Keep in mind that new drug research would come atop existing biosimilar clinical trials, which are expected to generate billions of dollars in future sales.</p>\n<p>Viatris won't deliver jaw-dropping growth like Jushi, or even double-digit annual sales upside like Exelixis. But with a steadiness to generic-drug demand and an improving balance sheet, Viatris' forward price-to-earnings ratio below 4 simply doesn't do its stock justice.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Smartest Stocks to Buy With $20 Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Smartest Stocks to Buy With $20 Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-12 21:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/11/12/the-smartest-stocks-to-buy-with-20-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Time and again, Wall Street has shown investors the power of patience.\nOver the past 71 years, the broad-based S&P 500 has undergone 38 double-digit percentage corrections. Despite the regularity of ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/12/the-smartest-stocks-to-buy-with-20-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"EXEL":"伊克力西斯","JUSHF":"Jushi Holdings Inc.","VTRS":"Viatris Inc."},"source_url":"https://www.fool.com/investing/2021/11/12/the-smartest-stocks-to-buy-with-20-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2182094779","content_text":"Time and again, Wall Street has shown investors the power of patience.\nOver the past 71 years, the broad-based S&P 500 has undergone 38 double-digit percentage corrections. Despite the regularity of these moves lower, every crash and correction throughout this period was eventually erased by a bull market rally. To put things succinctly, if investors buy great companies and allow their investment theses to play out over long periods of time, their chances of building wealth is very high.\nBest of all, with most online brokerages discarding minimum deposit requirements and commission fees, investors can begin or further their trek to financial independence with any amount of cash -- even $20. If you have $20 ready to put to work in the market, and it won't be needed to cover bills or other essential costs, the following trio of companies are the smartest stocks to buy right now.\nExelixis\nOne of the savviest stocks patient investors can buy right now with $20 is cancer-drug developer Exelixis (NASDAQ:EXEL).\nLast week, Exelixis announced its third-quarter operating results, which failed to hit the mark and sent its shares down by more than 10%. Sales of lead-drug Cabometyx were shy of Wall Street's expectations, which caused Exelixis to lower the upper end of its full-year sales outlook. Generally, lowering sales expectations will be met with frowns on Wall Street.\nHowever, this short-term weakness should be viewed as an opportunity, especially with the company's price-to-earnings-growth ratio (PEG ratio) below 0.4. A PEG ratio below 1 is typically considered \"undervalued.\"\nAlthough the landscape for first-line advanced renal cell carcinoma (RCC) is competitive, Cabometyx has demonstrated the ability to grow sales by a sustained double-digit percentage in RCC and advanced hepatocellular carcinoma. On an annual run-rate basis, Cabometyx is pacing more than $1 billion in sales -- and it's not done growing.\nMore importantly, Exelixis' lead drug is being examined in close to six dozen clinical trials as a monotherapy or combination treatment. If even a handful of these trials yield a positive result, label-expansion opportunities and organic growth could send Cabometyx to north of $2 billion in peak annual sales.\nAdditionally, Exelixis' robust cash position ($1.8 billion in cash, cash equivalents, and restricted cash) and healthy operating cash flow have allowed it to reignite its internal research engine. This includes advancing internally developed compounds into phase 1 studies, as well as signing collaboration agreements to potentially expand its cancer-drug pipeline.\nIt's not often you can marry growth and value with the same company, but that's exactly what investors can do with biotech stock Exelixis.\nJushi Holdings\nSome of the most deeply discounted growth stocks can be found in the marijuana industry, which is why U.S. multi-state operator (MSO) Jushi Holdings (OTC:JUSHF) makes for a smart buy with $20.\nTo start with, don't be concerned about a lack of cannabis reform in Washington. While life would undoubtedly be easier for pot stocks if lawmakers would simply follow the overwhelming will of the public and legalize cannabis, allowing individual states to legalize and regulate their pot industries is working fine. Thus far, 36 states have given the green light to weed in some capacity, which is providing growth opportunities for MSOs like Jushi.\nIn relative terms, Jushi is a small fry, with only 26 operating dispensaries at the moment. Comparatively, a handful of MSOs have in the neighborhood of (or more than) 100 open locations. But Jushi isn't about reckless expansion. Its management team favors methodical expansion in core markets. For Jushi, these core states are Pennsylvania, Illinois, and Virginia.\nThe reason management has chosen these states is due to their billion-dollar sales potential (Illinois hit $1 billion in legal pot revenue in 2020) and their limited-license status. In limited-license cannabis markets, regulators purposely limit how many dispensary licenses are issued in total, as well as to a single business. For a smaller player like Jushi, this competitive protection ensures it'll have a fair shot to build up its brand(s) and garner a loyal following in these core markets.\nSomething else impressive about Jushi, and one of the reasons I plan to be a long-term shareholder, is the participation of management and insiders. Of the first $250 million raised by the company, $45 million came from insiders and execs. When leadership has skin in the game right alongside their investors, good things tend to happen.\nJushi is expected to turn the corner to recurring profitability in 2022 and the company's growing sales faster than virtually all other MSOs. The company checks all the appropriate boxes for growth investors.\nViatris\nOn the other hand, if value runs through your blood, generic-drug giant Viatris (NASDAQ:VTRS) is one of the smartest stocks you can buy right now with $20.\nRoughly a year ago, Viatris was born from the combination of Pfizer's established drug unit Upjohn with generic-drug developer Mylan. Due to generic-drug price weakness throughout the industry, the company's first year as a public company has been one to forget. However, this near-term underperformance represents the perfect opportunity for patient investors to nab an exceptionally inexpensive and profitable drug stock.\nThere were a number of reasons Upjohn and Mylan tied the knot. First off, there were clear-cut cost synergies. The company expects to recognize more than $500 million in cost synergies this year, with well over $1 billion in annual cost reductions by 2023.\nAs a combined company, Viatris is also in a better position to tackle its outstanding debt. Through the first six months of 2021, $1.15 billion in debt was repaid. By the end of 2023, $6.5 billion in debt should be repaid, which represents a quarter of the company's combined debt ($26 billion), as of November 2020.\nBeyond just trimming the fat, Viatris should be able to kick-start its internal drug research in 2024 once debt levels are reduced to more favorable levels. Keep in mind that new drug research would come atop existing biosimilar clinical trials, which are expected to generate billions of dollars in future sales.\nViatris won't deliver jaw-dropping growth like Jushi, or even double-digit annual sales upside like Exelixis. But with a steadiness to generic-drug demand and an improving balance sheet, Viatris' forward price-to-earnings ratio below 4 simply doesn't do its stock justice.","news_type":1},"isVote":1,"tweetType":1,"viewCount":831,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":847777060,"gmtCreate":1636556464462,"gmtModify":1636556849281,"author":{"id":"3576666566979913","authorId":"3576666566979913","name":"YBinvest","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576666566979913","authorIdStr":"3576666566979913"},"themes":[],"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/847777060","repostId":"2182036772","repostType":4,"repost":{"id":"2182036772","kind":"highlight","pubTimestamp":1636553100,"share":"https://www.laohu8.com/m/news/2182036772?lang=&edition=full","pubTime":"2021-11-10 22:05","market":"us","language":"en","title":"3 Ultra-High-Yield Dividend Stocks With 42% to 50% Upside, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2182036772","media":"Motley Fool","summary":"These income stocks, with yields ranging between 8% and 8.3%, have Wall Street's attention.","content":"<p>Since the Great Recession ended more than 12 years ago, growth stocks have been the talk of Wall Street. Historically low lending rates and an accommodative Federal Reserve have paved the way for fast-paced companies to borrow cheaply in order to hire, acquire, and innovate.</p>\n<p>But look out over many decades and you'll find that dividend stocks have been the superior play. A report from J.P. Morgan Asset Management, a division of <b>JPMorgan Chase</b>, found the average annual return for companies that initiated and grew their payouts between 1972 and 2012 completely trounced the average annual return of companies that didn't pay a dividend over the same four-decade span (9.5% vs. 1.6%).</p>\n<p>While all eyes remain on growth stocks, some analysts on Wall Street foresee big upside for a handful of ultra-high-yield dividend stocks (i.e., companies arbitrarily defined as having yields of 7% or higher). Based on the high-water price targets from analysts, the following three ultra-high-yield stocks could rise 42% to as much as 50% over the next 12 months.</p>\n<h2>Enterprise Products Partners: 7.97% yield with 42% implied upside</h2>\n<p>First up is oil stock <b>Enterprise Products Partners</b> (NYSE:EPD), which <a href=\"https://laohu8.com/S/AONE.U\">one</a> Wall Street investment bank believes could reach $32 a share over the coming year. If this lofty price target proves accurate, investors would net 42% share price upside while also collecting an 8% yield.</p>\n<p>Although investors might be leery of putting their money to work in oil stocks given the historic demand drawdown witnessed in 2020 for crude oil, Enterprise Products doesn't come with these same concerns. That's because it's a midstream operator, with approximately 50,000 miles of pipeline, 14 billion cubic feet of natural gas storage, and 19 natural gas processing facilities. Whereas drillers are directly affected by the vacillations in crude oil and natural gas prices, midstream operators are usually insulated by the structure of their contracts. This is the case with Enterprise Products Partners.</p>\n<p>On the flipside, higher fossil fuel prices certainly won't hurt. With crude oil recently hitting a seven-year high, drillers are incented to boost production. Since Enterprise Products Partners regularly allots capital for infrastructure projects, higher crude oil and natural gas prices should lead to steady cash flow expansion.</p>\n<p>It's also worth mentioning how sturdy this payout has become. Even during the worst of the pandemic in 2020, the company's distribution coverage ratio never fell below 1.6 (anything below 1 would suggest an unsustainable payout). The distribution coverage ratio describes the amount of distributable cash flow for the company relative to the cash paid to shareholders.</p>\n<p>Enterprise Products Partners is riding a 22-year streak of increasing its base annual distribution and I see no reason why it won't hit 23 years in 2022.</p>\n<h2>AT&amp;T: 8.29% yield with 47% implied upside</h2>\n<p>Another ultra-high-yield dividend stock with serious upside potential is telecom giant <b>AT&amp;T </b>(NYSE:T). The highest price target on Wall Street of $37 suggests that this telco stalwart could appreciate up to 47% in the coming 12 months. Take note that while AT&amp;T is currently yielding 8.3%, this payout is expected to decline to closer to 4.5% to 5% in 2022 following the spinoff of WarnerMedia into a separate entity.</p>\n<p>Arguably the biggest catalyst for AT&amp;T is this expected combination of WarnerMedia with <b>Discovery</b> (NASDAQ:DISCA)(NASDAQ:DISCK) in the upcoming year. The new media entity, known as WarnerMedia-Discovery, will be better positioned to compete in a rapidly growing but competitive streaming landscape. In particular, original content and sporting events should help differentiate the new media entity from its key rivals. WarnerMedia-Discovery also expects to recognize at least $3 billion in annual cost synergies.</p>\n<p>As of September, this pro forma combination had a little over 85 million streaming subscribers. That's less than half of <b>Netflix</b>&nbsp;and it trails <b>Walt Disney</b>'s Disney+ streaming service. But according to current Discovery CEO David Zaslav, who'll be taking the helm at WarnerMedia-Discovery, hitting 400 million global streaming subscribers isn't out of the question.</p>\n<p>Beyond just gaining access to what should be a top-notch streaming company, AT&amp;T should benefit from the ongoing rollout of 5G wireless infrastructure. It's been a decade since wireless download speeds were meaningfully improved, which means the upgrade to 5G should encourage a multiyear consumer and enterprise device upgrade cycle. Since data is what drives the bulk of AT&amp;T's wireless margins, the company is well-positioned for sustainable organic growth through mid-decade.</p>\n<h2>Altria Group: 7.96% yield with 50% implied upside</h2>\n<p>But the crème de la crème of upside opportunity on this list is none other U.S. tobacco stock <b>Altria Group</b> (NYSE:MO). With a high-water price target on Wall Street of $68, the implication is shares of this 8%-yielding company could head higher by 50% over the next year.</p>\n<p>Altria, the company behind the premium Marlboro brand of cigarettes, has been challenged for decades by declining adult smoking rates in the United States. As the dangers of long-term tobacco use have come to light, the percentage of adults smoking tobacco cigarettes has declined from by two-thirds since the mid-1960s.</p>\n<p>However, this decline in adult smokers hasn't stopped the company from growing. One reason for that is Altria's superb pricing power. Tobacco contains nicotine, which is an addictive chemical. This addictive quality has allowed Altria to pass along steep price hikes, especially for its Marlboro brand, which more than outweigh any decline in cigarette shipment volumes.</p>\n<p>The company is also actively looking at new revenue channels that'll leave it less reliant on tobacco cigarettes. An example would be Altria's $1.8 billion equity investment in Canadian licensed cannabis producer <b>Cronos Group</b> (NASDAQ:CRON), which closed in March 2019. If and when the U.S. federal government legalizes marijuana, Cronos would be free to enter the U.S. market. The expectation is Altria will work with Cronos to develop, market, and distribute cannabis vape products, and perhaps other high-margin derivatives.</p>\n<p>It's worth pointing out that Altria owns a stake in vaping company Juul, as well.</p>\n<p>Though its days as a high-growth company are long gone, Altria continues to deliver for its shareholders. While 50% upside in 12 months is probably asking a bit much, long-term investors could certainly grow their wealth with Altria Group.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Ultra-High-Yield Dividend Stocks With 42% to 50% Upside, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Ultra-High-Yield Dividend Stocks With 42% to 50% Upside, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-10 22:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/11/10/3-ultra-high-yield-dividend-stocks-42-to-50-upside/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Since the Great Recession ended more than 12 years ago, growth stocks have been the talk of Wall Street. Historically low lending rates and an accommodative Federal Reserve have paved the way for fast...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/10/3-ultra-high-yield-dividend-stocks-42-to-50-upside/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"EPD":"Enterprise Products Partners L.P","MO":"奥驰亚","T":"美国电话电报"},"source_url":"https://www.fool.com/investing/2021/11/10/3-ultra-high-yield-dividend-stocks-42-to-50-upside/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2182036772","content_text":"Since the Great Recession ended more than 12 years ago, growth stocks have been the talk of Wall Street. Historically low lending rates and an accommodative Federal Reserve have paved the way for fast-paced companies to borrow cheaply in order to hire, acquire, and innovate.\nBut look out over many decades and you'll find that dividend stocks have been the superior play. A report from J.P. Morgan Asset Management, a division of JPMorgan Chase, found the average annual return for companies that initiated and grew their payouts between 1972 and 2012 completely trounced the average annual return of companies that didn't pay a dividend over the same four-decade span (9.5% vs. 1.6%).\nWhile all eyes remain on growth stocks, some analysts on Wall Street foresee big upside for a handful of ultra-high-yield dividend stocks (i.e., companies arbitrarily defined as having yields of 7% or higher). Based on the high-water price targets from analysts, the following three ultra-high-yield stocks could rise 42% to as much as 50% over the next 12 months.\nEnterprise Products Partners: 7.97% yield with 42% implied upside\nFirst up is oil stock Enterprise Products Partners (NYSE:EPD), which one Wall Street investment bank believes could reach $32 a share over the coming year. If this lofty price target proves accurate, investors would net 42% share price upside while also collecting an 8% yield.\nAlthough investors might be leery of putting their money to work in oil stocks given the historic demand drawdown witnessed in 2020 for crude oil, Enterprise Products doesn't come with these same concerns. That's because it's a midstream operator, with approximately 50,000 miles of pipeline, 14 billion cubic feet of natural gas storage, and 19 natural gas processing facilities. Whereas drillers are directly affected by the vacillations in crude oil and natural gas prices, midstream operators are usually insulated by the structure of their contracts. This is the case with Enterprise Products Partners.\nOn the flipside, higher fossil fuel prices certainly won't hurt. With crude oil recently hitting a seven-year high, drillers are incented to boost production. Since Enterprise Products Partners regularly allots capital for infrastructure projects, higher crude oil and natural gas prices should lead to steady cash flow expansion.\nIt's also worth mentioning how sturdy this payout has become. Even during the worst of the pandemic in 2020, the company's distribution coverage ratio never fell below 1.6 (anything below 1 would suggest an unsustainable payout). The distribution coverage ratio describes the amount of distributable cash flow for the company relative to the cash paid to shareholders.\nEnterprise Products Partners is riding a 22-year streak of increasing its base annual distribution and I see no reason why it won't hit 23 years in 2022.\nAT&T: 8.29% yield with 47% implied upside\nAnother ultra-high-yield dividend stock with serious upside potential is telecom giant AT&T (NYSE:T). The highest price target on Wall Street of $37 suggests that this telco stalwart could appreciate up to 47% in the coming 12 months. Take note that while AT&T is currently yielding 8.3%, this payout is expected to decline to closer to 4.5% to 5% in 2022 following the spinoff of WarnerMedia into a separate entity.\nArguably the biggest catalyst for AT&T is this expected combination of WarnerMedia with Discovery (NASDAQ:DISCA)(NASDAQ:DISCK) in the upcoming year. The new media entity, known as WarnerMedia-Discovery, will be better positioned to compete in a rapidly growing but competitive streaming landscape. In particular, original content and sporting events should help differentiate the new media entity from its key rivals. WarnerMedia-Discovery also expects to recognize at least $3 billion in annual cost synergies.\nAs of September, this pro forma combination had a little over 85 million streaming subscribers. That's less than half of Netflix and it trails Walt Disney's Disney+ streaming service. But according to current Discovery CEO David Zaslav, who'll be taking the helm at WarnerMedia-Discovery, hitting 400 million global streaming subscribers isn't out of the question.\nBeyond just gaining access to what should be a top-notch streaming company, AT&T should benefit from the ongoing rollout of 5G wireless infrastructure. It's been a decade since wireless download speeds were meaningfully improved, which means the upgrade to 5G should encourage a multiyear consumer and enterprise device upgrade cycle. Since data is what drives the bulk of AT&T's wireless margins, the company is well-positioned for sustainable organic growth through mid-decade.\nAltria Group: 7.96% yield with 50% implied upside\nBut the crème de la crème of upside opportunity on this list is none other U.S. tobacco stock Altria Group (NYSE:MO). With a high-water price target on Wall Street of $68, the implication is shares of this 8%-yielding company could head higher by 50% over the next year.\nAltria, the company behind the premium Marlboro brand of cigarettes, has been challenged for decades by declining adult smoking rates in the United States. As the dangers of long-term tobacco use have come to light, the percentage of adults smoking tobacco cigarettes has declined from by two-thirds since the mid-1960s.\nHowever, this decline in adult smokers hasn't stopped the company from growing. One reason for that is Altria's superb pricing power. Tobacco contains nicotine, which is an addictive chemical. This addictive quality has allowed Altria to pass along steep price hikes, especially for its Marlboro brand, which more than outweigh any decline in cigarette shipment volumes.\nThe company is also actively looking at new revenue channels that'll leave it less reliant on tobacco cigarettes. An example would be Altria's $1.8 billion equity investment in Canadian licensed cannabis producer Cronos Group (NASDAQ:CRON), which closed in March 2019. If and when the U.S. federal government legalizes marijuana, Cronos would be free to enter the U.S. market. The expectation is Altria will work with Cronos to develop, market, and distribute cannabis vape products, and perhaps other high-margin derivatives.\nIt's worth pointing out that Altria owns a stake in vaping company Juul, as well.\nThough its days as a high-growth company are long gone, Altria continues to deliver for its shareholders. While 50% upside in 12 months is probably asking a bit much, long-term investors could certainly grow their wealth with Altria Group.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1116,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"followers","isTTM":false}